Weekly Investment Analysts’ Ratings Updates for MannKind (MNKD)

A number of firms have modified their ratings and price targets on shares of MannKind (NASDAQ: MNKD) recently:

• 11/13/2025 – MannKind is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $7.00 price target on the stock.
• 11/11/2025 – MannKind had its price target lowered by analysts at Royal Bank Of Canada from $8.00 to $7.50. They now have an “outperform” rating on the stock.
• 11/11/2025 – MannKind had its price target lowered by analysts at Wells Fargo & Company from $10.00 to $8.00. They now have an “overweight” rating on the stock.
• 11/10/2025 – MannKind had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 11/8/2025 – MannKind was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/20/2025 – MannKind is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $10.00 price target on the stock.
• 10/13/2025 – MannKind had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
• 10/10/2025 – MannKind is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $9.00 price target on the stock.
• 10/8/2025 – MannKind had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 10/6/2025 – MannKind was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
• 9/27/2025 – MannKind had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at MannKind

In related news, insider Stuart A. Tross sold 47,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $5.34, for a total value of $250,980.00. Following the transaction, the insider owned 1,032,013 shares in the company, valued at approximately $5,510,949.42. This represents a 4.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sanjay R. Singh sold 18,777 shares of the business’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $5.03, for a total value of $94,448.31. Following the transaction, the executive vice president directly owned 455,211 shares of the company’s stock, valued at $2,289,711.33. The trade was a 3.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.70% of the stock is owned by company insiders.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.